Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | XBP1 | P17861 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GRK2 | P25098 | 7/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670010 | 1.00 | MAPT (0.58) | MAPTMAPK1XBP1MEN1KMT2A | |
| SCHEMBL3634197 | 0.86 | GRK2 (0.56) | MAPTMAPK1XBP1MEN1KMT2A | |
| SCHEMBL3634195 | 0.86 | GRK2 (0.56) | MAPTMAPK1XBP1MEN1KMT2A | |
| SCHEMBL690273 | 0.85 | GRK2 (0.65) | MAPTMAPK1MEN1KMT2AGRK2 | |
| SCHEMBL690272 | 0.85 | GRK2 (0.65) | MAPTMAPK1MEN1KMT2AGRK2 | |
| SCHEMBL1669195 | 0.85 | GRK2 (0.55) | MAPTMAPK1MEN1KMT2AGRK2 | |
| SCHEMBL1669192 | 0.85 | GRK2 (0.55) | MAPTMAPK1MEN1KMT2AGRK2 | |
| SCHEMBL3634227 | 0.84 | MAPT (0.51) | MAPTMAPK1XBP1MEN1KMT2A | |
| SCHEMBL3634230 | 0.84 | MAPT (0.51) | MAPTMAPK1XBP1MEN1KMT2A | |
| SCHEMBL14496352 | 0.81 | GRK2 (0.77) | MEN1KMT2AGRK2ROCK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142498-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | Institute for Oneworld Health (US) | 2010-01-13 | — | — | EP | claimed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | claimed |
| WO-2008121877-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH (US) | 2008-10-09 | — | — | WO | claimed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2490696-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048070-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-04-28 | — | — | WO | disclosed |
| EP-2142498-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | Institute for Oneworld Health (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| WO-2008121877-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | CFTR, IAPP, GPR119 | MAPT 4663/4885MAPK1 3174/4885XBP1 682/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | MAPT 4853/4885MAPK1 2060/4885XBP1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.